What’s Next for Antares Pharma Inc (ATRS) After Today’s Big Decline?

October 13, 2017 - By Hazel Jackson

Investors sentiment decreased to 2.07 in 2017 Q2. Its down 0.80, from 2.87 in 2017Q1. It fall, as 16 investors sold Antares Pharma Inc shares while 14 reduced holdings. 36 funds opened positions while 26 raised stakes. 53.64 million shares or 13.47% more from 47.27 million shares in 2017Q1 were reported.
Perkins Cap Mgmt Inc reported 10,000 shares stake. Pnc Fincl reported 0% of its portfolio in Antares Pharma Inc (NASDAQ:ATRS). Guggenheim Cap Ltd holds 0% of its portfolio in Antares Pharma Inc (NASDAQ:ATRS) for 403,975 shares. Group One Trading Limited Partnership holds 0% or 1,800 shares in its portfolio. First Eagle Investment Mngmt Limited Liability Corp invested in 0% or 20,000 shares. Highbridge Capital Mgmt Ltd Liability has invested 0% in Antares Pharma Inc (NASDAQ:ATRS). 1.19 million are owned by Geode Capital Mgmt Ltd Liability. Tfs Cap Limited Liability stated it has 0.02% in Antares Pharma Inc (NASDAQ:ATRS). Creative Planning owns 26,500 shares. M&T Bancorp Corporation stated it has 0% of its portfolio in Antares Pharma Inc (NASDAQ:ATRS). Commonwealth Equity holds 0% of its portfolio in Antares Pharma Inc (NASDAQ:ATRS) for 49,323 shares. State Board Of Administration Of Florida Retirement invested in 0% or 30,473 shares. New York-based Morgan Stanley has invested 0% in Antares Pharma Inc (NASDAQ:ATRS). Fuller And Thaler Asset Mngmt Incorporated reported 733,800 shares. Broadfin Cap Llc invested in 1.88% or 4.80 million shares.

Since June 9, 2017, it had 1 insider buy, and 0 sales for $363,272 activity.

The stock of Antares Pharma Inc (NASDAQ:ATRS) is a huge mover today! About 16.04M shares traded or 671.15% up from the average. Antares Pharma Inc (NASDAQ:ATRS) has risen 207.14% since October 14, 2016 and is uptrending. It has outperformed by 190.44% the S&P500.
The move comes after 5 months negative chart setup for the $362.86M company. It was reported on Oct, 14 by Barchart.com. We have $2.14 PT which if reached, will make NASDAQ:ATRS worth $21.77 million less.

Analysts expect Antares Pharma Inc (NASDAQ:ATRS) to report $-0.03 EPS on November, 8.They anticipate $0.01 EPS change or 25.00 % from last quarter’s $-0.04 EPS. After having $-0.02 EPS previously, Antares Pharma Inc’s analysts see 50.00 % EPS growth.

Antares Pharma Inc (NASDAQ:ATRS) Ratings Coverage

Among 4 analysts covering Antares Pharma (NASDAQ:ATRS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Antares Pharma had 7 analyst reports since March 9, 2016 according to SRatingsIntel. Jefferies maintained it with “Buy” rating and $600 target in Monday, August 7 report. Jefferies maintained Antares Pharma Inc (NASDAQ:ATRS) on Wednesday, March 9 with “Buy” rating. The firm earned “Buy” rating on Friday, June 23 by H.C. Wainwright. The stock of Antares Pharma Inc (NASDAQ:ATRS) earned “Buy” rating by Jefferies on Tuesday, October 10. The stock of Antares Pharma Inc (NASDAQ:ATRS) has “Buy” rating given on Friday, September 8 by H.C. Wainwright. The firm has “Buy” rating by Piper Jaffray given on Tuesday, July 25.

More important recent Antares Pharma Inc (NASDAQ:ATRS) news were published by: Marketwatch.com which released: “Antares Pharma stock plunges more than 30% after FDA letter” on October 12, 2017, also Fool.com published article titled: “Why Antares Pharma Inc Plummeted Today”, Seekingalpha.com published: “Antares Pharma: Will October Deliver A Triple Play?” on October 09, 2017. More interesting news about Antares Pharma Inc (NASDAQ:ATRS) was released by: Seekingalpha.com and their article: “Antares Pharma (ATRS)” with publication date: October 02, 2017.

Antares Pharma, Inc. is a specialty pharmaceutical firm that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The company has market cap of $362.86 million. The Firm develops and makes pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. It currently has negative earnings. The Company’s subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.